LYNBROOK, N.Y., Nov. 7, 2017 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that
originated and continues to develop collagenase based-therapies
with a first in class collagenase-based product marketed as
XIAFLEX® in the U.S. and Xiapex® in Europe, today
announced that BioSpecifics' President, Tom
Wegman, will present a corporate overview at the upcoming
Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 3:30 p.m. ET in New
York, NY.
A live webcast of the presentation can be accessed under "Events
and Presentation" in the Investors section of the Company's website
at www.biospecifics.com or at
http://wsw.com/webcast/stifel10/bstc/.
About BioSpecifics Technologies Corp.
BioSpecifics
Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for thirteen clinical indications
to date. Injectable collagenase is marketed as XIAFLEX® in the
U.S. for the treatment of Dupuytren's contracture and Peyronie's
disease by BioSpecifics' partner, Endo International plc (Endo).
XIAFLEX® is also commercialized
in Japan, Europe, Canada and Australia for
Dupuytren's contracture and for Peyronie's disease in Europe
and Australia. Endo is partnered with Paladin Labs in
Canada for Dupuytren's
Contracture. The XIAFLEX research and development pipeline includes
several additional promising indications. BioSpecifics is managing
the development of XIAFLEX for uterine fibroids and is conducting a
Phase 1 clinical trial. For more information, please
visit www.biospecifics.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-stifel-2017-healthcare-conference-300550517.html
SOURCE BioSpecifics Technologies Corp.